Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation

Avishay Grupper, Yanjun M. Zhao, Pavol Sajgalik, Lyle D. Joyce, Soon J. Park, Naveen Luke Pereira, John M. Stulak, John C Jr. Burnett, Brooks Sayre Edwards, Richard C. Daly, Sudhir S. Kushwaha, John A. Schirger

Research output: Contribution to journalArticle

4 Scopus citations


Neurohormonal blockade drug therapy (NHBDT) is the cornerstone therapy in heart failure (HF) management for promoting reverse cardiac remodeling and improving outcomes. It's utility in left ventricular assist device (LVAD) supported patients remains undefined. Sixty-four patients who received continuous flow LVAD at our institution were retrospectively reviewed and divided into 2 groups: no-NHBDT group (n = 33) received LVAD support only and NHBDT group (n = 31) received concurrent NHBDT based on the clinical judgment of the attending physicians. Cardiac remodeling (echocardiographic parameters and biomarkers) and clinical outcome (functional status, HF-related hospital readmissions, and mortality) data were collected. A statistically significant increase in ejection fraction, decrease in LV end-diastolic diameter index and LV mass index, and a sustained reduction in N-terminal pro B-type natriuretic peptide (NTproBNP) were observed in the NHBDT group at 6 months after LVAD implant (p

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
StateAccepted/In press - Jan 18 2016


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this